Osarhumwese Osaretin Ojo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Osarhumwese Osaretin Ojo has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Omorogieva Ojo
School of Health Sciences, Faculty of Education, Health and Human Sciences, University of Greenwich, Avery Hill Campus, London SE9 2UG, UK
14 shared publications - Xiaohua Wang
The School of Nursing, Soochow University, Suzhou 215006, China
12 shared publications - Amanda Rodrigues Amorim Adegboye
Coventry University
6 shared publications - Joanne Brooke
Centre of Social Care, Health, and Related Research, Birmingham City University, Westbourne Rd., Birmingham B15 3TN, UK
6 shared publications - Qianqian Feng
The School of Nursing, Soochow University, Suzhou 215006, China
4 shared publications - Ivy Kazangarare
School of Health Sciences, Faculty of Education, Health and Human Sciences, University of Greenwich, Avery Hill Campus, London SE9 2UG, UK
2 shared publications
Latest Publications
- Open Access
- 28 August 2025
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22  (9) , 1352
Current Advances and Future Prospects in the Use of a Low-Carbohydrate Diet in Managing People with Type 2 Diabetes: A Systematic Review of Randomised Controlled Trials
Background: There is a worldwide increase in the prevalence of type 2 diabetes, and strategies for managing this condition include dietary interventions. These interventions include the use of a low-glycaemic index diet, high-fibre and prebiotic diets, and low-carbohydrate diets (LCDs), which improve glycaemic control, reduce the risk of diabetic complications, and promote health. However, the definition of LCDs varies across the literature, and the use of LCDs in managing people with diabetes is often seen as controversial. Therefore, the aim of this review is to examine current advances and future prospects in the use of LCDs in managing people with type 2 diabetes. Method: A systematic review of randomised controlled trials, which applied both the PRISMA and PICOS frameworks. Databases including MEDLINE, APA PsycInfo, Academic Search Premier, CINAHL Plus with Full Text, APA PsycArticles, and Psychology and Behavioural Sciences Collection were searched through EBSCOHost. The EMBASE database and reference list of articles were also searched for articles of interest. Two researchers conducted the searches independently from database inception to 28 August 2025. However, based on the inclusion criteria, the year of publication of studies was restricted to articles published from 2021. The search terms were combined using Boolean operators (AND/OR), and duplicates were removed in EndNote. The articles were screened for eligibility based on inclusion and exclusion criteria by two researchers. Results: The findings identified that an LCD is significantly (p < 0.05) more effective in reducing glycaemic parameters compared to a usual diet, standard care, or a control diet in people with type 2 diabetes. Similarly, the effect of LCD was significant (p < 0.05) in reducing BMI in patients with type 2 diabetes compared with the control diet. However, an LCD did not appear to have a significant (p > 0.05) effect on lipid parameters compared to a control diet. Conclusion: This systematic review found that LCDs are significantly (p < 0.05) more effective in promoting glycaemic control than a usual diet, standard care, or a control diet in people with type 2 diabetes. In addition, LCDs can be an effective strategy for reducing BMI in individuals with type 2 diabetes, particularly when implemented as part of a structured, sustained dietary intervention. However, there was variability in the findings of the studies included with respect to glycaemic control and BMI. Furthermore, the impact of LCD on glycaemic control did not appear sustainable in the long term. LCDs did not have a significant (p > 0.05) effect on lipid parameters compared to a control diet.
- 28 August 2025
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22  (9) , 1352
Open AccessCurrent Advances and Future Prospects in the Use of a Low-Carbohydrate Diet in Managing People with Type 2 Diabetes: A Systematic Review of Randomised Controlled Trials
Background: There is a worldwide increase in the prevalence of type 2 diabetes, and strategies for managing this condition include dietary interventions. These interventions include the use of a low-glycaemic index diet, high-fibre and prebiotic diets, and low-carbohydrate diets (LCDs), which improve glycaemic control, reduce the risk of diabetic complications, and promote health. However, the definition of LCDs varies across the literature, and the use of LCDs in managing people with diabetes is often seen as controversial. Therefore, the aim of this review is to examine current advances and future prospects in the use of LCDs in managing people with type 2 diabetes. Method: A systematic review of randomised controlled trials, which applied both the PRISMA and PICOS frameworks. Databases including MEDLINE, APA PsycInfo, Academic Search Premier, CINAHL Plus with Full Text, APA PsycArticles, and Psychology and Behavioural Sciences Collection were searched through EBSCOHost. The EMBASE database and reference list of articles were also searched for articles of interest. Two researchers conducted the searches independently from database inception to 28 August 2025. However, based on the inclusion criteria, the year of publication of studies was restricted to articles published from 2021. The search terms were combined using Boolean operators (AND/OR), and duplicates were removed in EndNote. The articles were screened for eligibility based on inclusion and exclusion criteria by two researchers. Results: The findings identified that an LCD is significantly (p < 0.05) more effective in reducing glycaemic parameters compared to a usual diet, standard care, or a control diet in people with type 2 diabetes. Similarly, the effect of LCD was significant (p < 0.05) in reducing BMI in patients with type 2 diabetes compared with the control diet. However, an LCD did not appear to have a significant (p > 0.05) effect on lipid parameters compared to a control diet. Conclusion: This systematic review found that LCDs are significantly (p < 0.05) more effective in promoting glycaemic control than a usual diet, standard care, or a control diet in people with type 2 diabetes. In addition, LCDs can be an effective strategy for reducing BMI in individuals with type 2 diabetes, particularly when implemented as part of a structured, sustained dietary intervention. However, there was variability in the findings of the studies included with respect to glycaemic control and BMI. Furthermore, the impact of LCD on glycaemic control did not appear sustainable in the long term. LCDs did not have a significant (p > 0.05) effect on lipid parameters compared to a control diet.
- Open Access
- 6 June 2025
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22  (6) , 910
The Effect of Type 2 Diabetes on Bone Quality: A Systematic Review and Meta-Analysis of Cohort Studies
Background: There is a significant knowledge gap and limited studies have been carried out to evaluate the effect of type 2 diabetes (T2D) on bone quality and skeletal fragility. Previous reviews have tended to focus primarily on bone mineral density (BMD) as a measure of bone quality. However, BMD does not fully reflect the risk of fracture, cannot distinguish between cortical and trabecular bone, and bone fragility in patients with T2D results not only from alterations in bone mineralisation, but also due to changes in bone microarchitecture. In this regard, assessment tools such as trabecular bone score (TBS) and trabecular microarchitectural parameters could be useful and practical tools for examining bone status in people with T2D. Aim: This review aims to examine the effect of type 2 diabetes on bone quality based on a variety of assessment tools. Method: The PRISMA checklist and PICOS framework were relied on for this systematic review and meta-analysis. Two researchers conducted the searches from database inception until 24/02/25. Databases including Academic Search Premier, APA PsycArticles, APA PsycInfo, CINAHL Plus with Full Text, MEDLINE, and the Psychology & Behavioral Sciences Collection were searched for relevant articles. The reference lists of articles were also searched. The Review Manager 5.4.1 software was used to carry out the meta-analysis. Results: Ten studies were included in the systematic review, while nine studies were included in the meta-analysis. Based on the narrative synthesis and meta-analysis, four distinct themes were established: bone mineral density, TBS and trabecular microarchitectural parameters, fracture risk, and body mass index (BMI). The meta-analysis of the effect of T2D on BMD showed that T2D significantly (p < 0.05) increased lumbar spine, total hip, femoral neck, and narrow neck BMD compared with controls. The mean differences (MDs) for the respective parameters were 0.04 (95% CI, 0.03, 0.05, p < 0.0001); 0.05 (95% CI, 0.02, 0.08, p = 0.002); 0.07 (95% CI, 0.04, 0.10, p < 0.0001); and 0.03 (95% CI, 0.01, 0.05, p = 0.0005). While there was a significant reduction (p < 0.0001) in the patients with T2D with respect to volumetric BMD, involving two studies and 1037 participants, with an MD of −12.36 (95% CI,−18.15, −6.57, p < 0.0001), T2D did not appear to have a significant effect (p > 0.05) on total BMD and area BMD compared to controls. In relation to TBS and trabecular microarchitectural parameters, the effect of T2D was not significant (p > 0.05) compared with controls. Furthermore, T2D did not have a significant effect (p > 0.05) on the incidence of hip fracture and non-spine fracture compared to controls. Following meta-analysis, it was found that the T2D significantly (p < 0.05) increased BMI compared to controls with an MD of 0.94 (95% CI, 0.74, 1.14, p < 0.0001). Conclusions: Type 2 diabetes significantly increased (p < 0.05) lumbar spine, total hip, femoral neck, narrow neck BMD, and body mass index compared with controls. However, type 2 diabetes did not appear to have a significant effect (p > 0.05) on TBS, trabecular microarchitectural parameters, and the incidence of hip and non-spine fracture.
- 6 June 2025
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22  (6) , 910
Open AccessThe Effect of Type 2 Diabetes on Bone Quality: A Systematic Review and Meta-Analysis of Cohort Studies
Background: There is a significant knowledge gap and limited studies have been carried out to evaluate the effect of type 2 diabetes (T2D) on bone quality and skeletal fragility. Previous reviews have tended to focus primarily on bone mineral density (BMD) as a measure of bone quality. However, BMD does not fully reflect the risk of fracture, cannot distinguish between cortical and trabecular bone, and bone fragility in patients with T2D results not only from alterations in bone mineralisation, but also due to changes in bone microarchitecture. In this regard, assessment tools such as trabecular bone score (TBS) and trabecular microarchitectural parameters could be useful and practical tools for examining bone status in people with T2D. Aim: This review aims to examine the effect of type 2 diabetes on bone quality based on a variety of assessment tools. Method: The PRISMA checklist and PICOS framework were relied on for this systematic review and meta-analysis. Two researchers conducted the searches from database inception until 24/02/25. Databases including Academic Search Premier, APA PsycArticles, APA PsycInfo, CINAHL Plus with Full Text, MEDLINE, and the Psychology & Behavioral Sciences Collection were searched for relevant articles. The reference lists of articles were also searched. The Review Manager 5.4.1 software was used to carry out the meta-analysis. Results: Ten studies were included in the systematic review, while nine studies were included in the meta-analysis. Based on the narrative synthesis and meta-analysis, four distinct themes were established: bone mineral density, TBS and trabecular microarchitectural parameters, fracture risk, and body mass index (BMI). The meta-analysis of the effect of T2D on BMD showed that T2D significantly (p < 0.05) increased lumbar spine, total hip, femoral neck, and narrow neck BMD compared with controls. The mean differences (MDs) for the respective parameters were 0.04 (95% CI, 0.03, 0.05, p < 0.0001); 0.05 (95% CI, 0.02, 0.08, p = 0.002); 0.07 (95% CI, 0.04, 0.10, p < 0.0001); and 0.03 (95% CI, 0.01, 0.05, p = 0.0005). While there was a significant reduction (p < 0.0001) in the patients with T2D with respect to volumetric BMD, involving two studies and 1037 participants, with an MD of −12.36 (95% CI,−18.15, −6.57, p < 0.0001), T2D did not appear to have a significant effect (p > 0.05) on total BMD and area BMD compared to controls. In relation to TBS and trabecular microarchitectural parameters, the effect of T2D was not significant (p > 0.05) compared with controls. Furthermore, T2D did not have a significant effect (p > 0.05) on the incidence of hip fracture and non-spine fracture compared to controls. Following meta-analysis, it was found that the T2D significantly (p < 0.05) increased BMI compared to controls with an MD of 0.94 (95% CI, 0.74, 1.14, p < 0.0001). Conclusions: Type 2 diabetes significantly increased (p < 0.05) lumbar spine, total hip, femoral neck, narrow neck BMD, and body mass index compared with controls. However, type 2 diabetes did not appear to have a significant effect (p > 0.05) on TBS, trabecular microarchitectural parameters, and the incidence of hip and non-spine fracture.
- Open Access
- 13 April 2023
- Published by MDPI AG in Healthcare
- Vol. 11  (8) , 1120
The Association of Planetary Health Diet with the Risk of Type 2 Diabetes and Related Complications: A Systematic Review
Background: Nutritional interventions such as the planetary health diet, which the EAT-Lancet commission proposed, may be an effective strategy for reducing type 2 diabetes risks and its associated complications. The planetary health diet demonstrates the significant role of diet in associating human health with environmental sustainability and the significance of transforming food systems in order to ensure that the UN’s Sustainable Development Goals and the Paris Agreement are achieved. Therefore, the aim of this review is to examine the association of the planetary health diet (PHD) with the risk of type 2 diabetes and its related complications. Method: The systematic review was conducted in line with established guidelines. The searches were carried out in health sciences research databases through EBSCOHost. The population, intervention, comparator and outcomes framework was used in order to define the research question and the search terms. The searches were carried out from the inception of the databases to 15 November 2022. Search terms including synonyms and medical subject headings were combined using Boolean operators (OR/AND). Results: Seven studies were included in the review and four themes were identified, including incidence of diabetes; cardiovascular risk factors and other disease risks; indicators of obesity and indicators of environmental sustainability. Two studies examined the association between the PHD and the incidence of type 2 diabetes and found that high adherence to the reference diet (EAT-Lancet reference diet) was correlated with a lower incidence of type 2 diabetes. High adherence to the PHD was also associated with some cardiovascular risk factors and environmental sustainability. Conclusion: This systematic review has shown that high adherence to the PHD is associated with a reduced risk of type 2 diabetes and may be associated with a lower risk of subarachnoid stroke. In addition, an inverse relationship was found between adherence to the PHD and markers of obesity and environmental sustainability. Adherence to the reference diet was also associated with lower values of some markers of cardiovascular risk. More studies are needed to fully examine the relationship between the planetary health diet, type 2 diabetes and its related conditions.
- 13 April 2023
- Published by MDPI AG in Healthcare
- Vol. 11  (8) , 1120
Open AccessThe Association of Planetary Health Diet with the Risk of Type 2 Diabetes and Related Complications: A Systematic Review
Background: Nutritional interventions such as the planetary health diet, which the EAT-Lancet commission proposed, may be an effective strategy for reducing type 2 diabetes risks and its associated complications. The planetary health diet demonstrates the significant role of diet in associating human health with environmental sustainability and the significance of transforming food systems in order to ensure that the UN’s Sustainable Development Goals and the Paris Agreement are achieved. Therefore, the aim of this review is to examine the association of the planetary health diet (PHD) with the risk of type 2 diabetes and its related complications. Method: The systematic review was conducted in line with established guidelines. The searches were carried out in health sciences research databases through EBSCOHost. The population, intervention, comparator and outcomes framework was used in order to define the research question and the search terms. The searches were carried out from the inception of the databases to 15 November 2022. Search terms including synonyms and medical subject headings were combined using Boolean operators (OR/AND). Results: Seven studies were included in the review and four themes were identified, including incidence of diabetes; cardiovascular risk factors and other disease risks; indicators of obesity and indicators of environmental sustainability. Two studies examined the association between the PHD and the incidence of type 2 diabetes and found that high adherence to the reference diet (EAT-Lancet reference diet) was correlated with a lower incidence of type 2 diabetes. High adherence to the PHD was also associated with some cardiovascular risk factors and environmental sustainability. Conclusion: This systematic review has shown that high adherence to the PHD is associated with a reduced risk of type 2 diabetes and may be associated with a lower risk of subarachnoid stroke. In addition, an inverse relationship was found between adherence to the PHD and markers of obesity and environmental sustainability. Adherence to the reference diet was also associated with lower values of some markers of cardiovascular risk. More studies are needed to fully examine the relationship between the planetary health diet, type 2 diabetes and its related conditions.
- Open Access
The Effect of Prebiotics and Oral Anti-Diabetic Agents on Gut Microbiome in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials
Background: Nutritional interventions such as the use of prebiotics can promote eubiosis of gut microbiome and maintain glucose homeostasis in patients with type 2 diabetes (T2D). However, it would appear that results of the effects of prebiotics on the community of microbes in the gut are not consistent. Aim: To examine the effect of prebiotics and oral antidiabetic agents on gut microbiome in patients with T2D. Methods: The PRISMA Extension Statement for Systematic Reviews and Network Meta-analyses was used to conduct this review. Searches were carried out in EMBASE, EBSCO-host databases, Google Scholar and the reference lists of articles for studies that are relevant to the research question, from database inception to 15 August 2022. The search strategy was based on PICOS framework. Network Meta-analysis which allows the estimation of relative treatment effects by combing both direct trial evidence (e.g., treatment A vs. treatment B) and indirect evidence was conducted. Furthermore, pairwise meta-analysis was also carried out to estimate effect sizes based on head-to-head comparisons of treatments and/or control conditions. Results: Findings of the Network meta-analysis revealed that prebiotics significantly reduced HbA1c compared with control and the SMD was −0.43 [95% CI, −0.77, −0.08; p = 0.02], whereas there was no significant difference (p > 0.05) between the other treatments and control. In addition, anti-diabetic agents including glipizide and metformin also reduced HbA1C, although these were not significantly different (p > 0.05) from control. While prebiotics promoted Bifidobacterium and Akkermansia, the improvements were not significantly different (p > 0.05) from control. On the other hand, metformin decreased the relative abundance of Bifidobacterium, but increased Lactobacillus and Akkermansia, although the differences were not significant (p > 0.05) compared with control. With respect to fasting blood glucose and BMI, the effects of prebiotics and oral antidiabetic agents did not differ significantly (p > 0.05) from controls. Conclusions: The findings of the systematic review and Network meta-analysis demonstrated prebiotics were significantly (p < 0.05) more effective in reducing HbA1c than control in patients with T2D. However, the effects of prebiotics and oral antidiabetic agents did not differ significantly (p > 0.05) from the controls in relation to fasting blood glucose, post-prandial blood glucose, body mass index and the genera of gut bacteria examined. More studies are required to fully investigate the effects of prebiotics and oral antidiabetic agents in patients with T2D
Open AccessThe Effect of Prebiotics and Oral Anti-Diabetic Agents on Gut Microbiome in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials
Background: Nutritional interventions such as the use of prebiotics can promote eubiosis of gut microbiome and maintain glucose homeostasis in patients with type 2 diabetes (T2D). However, it would appear that results of the effects of prebiotics on the community of microbes in the gut are not consistent. Aim: To examine the effect of prebiotics and oral antidiabetic agents on gut microbiome in patients with T2D. Methods: The PRISMA Extension Statement for Systematic Reviews and Network Meta-analyses was used to conduct this review. Searches were carried out in EMBASE, EBSCO-host databases, Google Scholar and the reference lists of articles for studies that are relevant to the research question, from database inception to 15 August 2022. The search strategy was based on PICOS framework. Network Meta-analysis which allows the estimation of relative treatment effects by combing both direct trial evidence (e.g., treatment A vs. treatment B) and indirect evidence was conducted. Furthermore, pairwise meta-analysis was also carried out to estimate effect sizes based on head-to-head comparisons of treatments and/or control conditions. Results: Findings of the Network meta-analysis revealed that prebiotics significantly reduced HbA1c compared with control and the SMD was −0.43 [95% CI, −0.77, −0.08; p = 0.02], whereas there was no significant difference (p > 0.05) between the other treatments and control. In addition, anti-diabetic agents including glipizide and metformin also reduced HbA1C, although these were not significantly different (p > 0.05) from control. While prebiotics promoted Bifidobacterium and Akkermansia, the improvements were not significantly different (p > 0.05) from control. On the other hand, metformin decreased the relative abundance of Bifidobacterium, but increased Lactobacillus and Akkermansia, although the differences were not significant (p > 0.05) compared with control. With respect to fasting blood glucose and BMI, the effects of prebiotics and oral antidiabetic agents did not differ significantly (p > 0.05) from controls. Conclusions: The findings of the systematic review and Network meta-analysis demonstrated prebiotics were significantly (p < 0.05) more effective in reducing HbA1c than control in patients with T2D. However, the effects of prebiotics and oral antidiabetic agents did not differ significantly (p > 0.05) from the controls in relation to fasting blood glucose, post-prandial blood glucose, body mass index and the genera of gut bacteria examined. More studies are required to fully investigate the effects of prebiotics and oral antidiabetic agents in patients with T2D
- Open Access
The Effects of Enteral Nutrition in Critically Ill Patients with COVID-19: A Systematic Review and Meta-Analysis
Background: Patients who are critically ill with COVID-19 could have impaired nutrient absorption due to disruption of the normal intestinal mucosa. They are often in a state of high inflammation, increased stress and catabolism as well as a significant increase in energy and protein requirements. Therefore, timely enteral nutrition support and the provision of optimal nutrients are essential in preventing malnutrition in these patients. Aim: This review aims to evaluate the effects of enteral nutrition in critically ill patients with COVID-19. Method: This systematic review and meta-analysis was conducted based on the preferred reporting items for systematic review and meta-Analysis framework and PICO. Searches were conducted in databases, including EMBASE, Health Research databases and Google Scholar. Searches were conducted from database inception until 3 February 2022. The reference lists of articles were also searched for relevant articles. Results: Seven articles were included in the systematic review, and four articles were included in the meta-analysis. Two distinct areas were identified from the results of the systematic review and meta-analysis: the impact of enteral nutrition and gastrointestinal intolerance associated with enteral nutrition. The impact of enteral nutrition was further sub-divided into early enteral nutrition versus delayed enteral nutrition and enteral nutrition versus parenteral nutrition. The results of the meta-analysis of the effects of enteral nutrition in critically ill patients with COVID-19 showed that, overall, enteral nutrition was effective in significantly reducing the risk of mortality in these patients compared with the control with a risk ratio of 0.89 (95% CI, 0.79, 0.99, p = 0.04). Following sub-group analysis, the early enteral nutrition group also showed a significant reduction in the risk of mortality with a risk ratio of 0.89 (95% CI, 0.79, 1.00, p = 0.05). The Relative Risk Reduction (RRR) of mortality in patients with COVID-19 by early enteral nutrition was 11%. There was a significant reduction in the Sequential Organ Failure Assessment (SOFA) score in the early enteral nutrition group compared with the delayed enteral nutrition group. There was no significant difference between enteral nutrition and parenteral nutrition in relation to mortality (RR = 0.87; 95% CI, 0.59, 1.28, p = 0.48). Concerning the length of hospital stay, length of ICU stay and days on mechanical ventilation, while there were reductions in the number of days in the enteral nutrition group compared to the control (delayed enteral nutrition or parenteral nutrition), the differences were not significant (p > 0.05). Conclusion: The results showed that early enteral nutrition significantly (p < 0.05) reduced the risk of mortality among critically ill patients with COVID-19. However, early enteral nutrition or enteral nutrition did not significantly (p > 0.05) reduce the length of hospital stay, length of ICU stay and days on mechanical ventilation compared to delayed enteral nutrition or parenteral nutrition. More studies are needed to examine the effect of early enteral nutrition in patients with COVID-19.
Open AccessThe Effects of Enteral Nutrition in Critically Ill Patients with COVID-19: A Systematic Review and Meta-Analysis
Background: Patients who are critically ill with COVID-19 could have impaired nutrient absorption due to disruption of the normal intestinal mucosa. They are often in a state of high inflammation, increased stress and catabolism as well as a significant increase in energy and protein requirements. Therefore, timely enteral nutrition support and the provision of optimal nutrients are essential in preventing malnutrition in these patients. Aim: This review aims to evaluate the effects of enteral nutrition in critically ill patients with COVID-19. Method: This systematic review and meta-analysis was conducted based on the preferred reporting items for systematic review and meta-Analysis framework and PICO. Searches were conducted in databases, including EMBASE, Health Research databases and Google Scholar. Searches were conducted from database inception until 3 February 2022. The reference lists of articles were also searched for relevant articles. Results: Seven articles were included in the systematic review, and four articles were included in the meta-analysis. Two distinct areas were identified from the results of the systematic review and meta-analysis: the impact of enteral nutrition and gastrointestinal intolerance associated with enteral nutrition. The impact of enteral nutrition was further sub-divided into early enteral nutrition versus delayed enteral nutrition and enteral nutrition versus parenteral nutrition. The results of the meta-analysis of the effects of enteral nutrition in critically ill patients with COVID-19 showed that, overall, enteral nutrition was effective in significantly reducing the risk of mortality in these patients compared with the control with a risk ratio of 0.89 (95% CI, 0.79, 0.99, p = 0.04). Following sub-group analysis, the early enteral nutrition group also showed a significant reduction in the risk of mortality with a risk ratio of 0.89 (95% CI, 0.79, 1.00, p = 0.05). The Relative Risk Reduction (RRR) of mortality in patients with COVID-19 by early enteral nutrition was 11%. There was a significant reduction in the Sequential Organ Failure Assessment (SOFA) score in the early enteral nutrition group compared with the delayed enteral nutrition group. There was no significant difference between enteral nutrition and parenteral nutrition in relation to mortality (RR = 0.87; 95% CI, 0.59, 1.28, p = 0.48). Concerning the length of hospital stay, length of ICU stay and days on mechanical ventilation, while there were reductions in the number of days in the enteral nutrition group compared to the control (delayed enteral nutrition or parenteral nutrition), the differences were not significant (p > 0.05). Conclusion: The results showed that early enteral nutrition significantly (p < 0.05) reduced the risk of mortality among critically ill patients with COVID-19. However, early enteral nutrition or enteral nutrition did not significantly (p > 0.05) reduce the length of hospital stay, length of ICU stay and days on mechanical ventilation compared to delayed enteral nutrition or parenteral nutrition. More studies are needed to examine the effect of early enteral nutrition in patients with COVID-19.
- Open Access
- 19 January 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19  (3) , 1095
The Effects of COVID-19 Lockdown on Glycaemic Control and Lipid Profile in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
The impact of the COVID-19 lockdown on glycaemic control and other metabolic parameters in patients with type 2 diabetes is still evolving. Aim: This systematic review and meta-analysis aims to examine the effects of COVID-19 lockdown on glycaemic control and lipid profile in patients with type 2 diabetes. Methods: The PRISMA framework was the method used to conduct the systematic review and meta-analysis, and the search strategy was based on the population, intervention, control and outcome (PICO) model. The Health Sciences Research databases was accessed via EBSCO-host, and EMBASE were searched for relevant articles. Searches were conducted from inception of the databases until 17 September 2021. Results: The results identified three distinct areas: glycaemic control, lipid parameters and body mass index. It was found that COVID-19 lockdown led to a significant (p < 0.01) increase in the levels of glycated haemoglobin (%) compared with pre-COVID group (gp) with a mean difference of 0.34 (95% CI: 0.30, 0.38). Eleven studies contributed to the data for glycated haemoglobin analysis with a total of 16,895 participants (post-COVID-19 lockdown gp, n = 8417; pre-COVID gp, n = 8478). The meta-analysis of fasting plasma glucose (mg/dL) also showed a significant (p < 0.05) increase in levels of post-COVID-19 lockdown gp compared with pre-COVID gp, with a mean difference of 7.19 (95% CI: 5.28, 9.10). Six studies contributed to fasting plasma glucose analysis involving a total of 2327 participants (post-COVID-19 lockdown, n = 1159; pre-COVID gp, n = 1168). The body mass index (BMI) (kg/m2) analysis also demonstrated that post-COVID-19 lockdown gp had a significantly (p < 0.05) higher BMI than the pre-COVID gp with a mean difference of 1.13 (95% CI: 0.99; 1.28), involving six studies and a total of 2363 participants (post-COVID-19 lockdown gp, n = 1186; pre-COVID gp, n = 1177). There were significantly (p < 0.05) lower levels of total cholesterol (mmol/L), triglyceride (mmol/L) and LDL cholesterol (mmol/L), and higher levels of HDL cholesterol (mg/dL) in the post-COVID-19 lockdown gp compared with pre-COVID gp, although these results were not consistent following sensitivity analysis. Conclusion: The findings of the systematic review and meta-analysis have demonstrated that COVID-19 lockdown resulted in a significant increase (p < 0.05) in the levels of glycated haemoglobin, fasting glucose and body mass index in patients with type 2 diabetes. In contrast, the effect of the lockdown on lipid parameters, including total cholesterol, triglycerides, LDL and HDL cholesterol was not consistent.
- 19 January 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19  (3) , 1095
Open AccessThe Effects of COVID-19 Lockdown on Glycaemic Control and Lipid Profile in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
The impact of the COVID-19 lockdown on glycaemic control and other metabolic parameters in patients with type 2 diabetes is still evolving. Aim: This systematic review and meta-analysis aims to examine the effects of COVID-19 lockdown on glycaemic control and lipid profile in patients with type 2 diabetes. Methods: The PRISMA framework was the method used to conduct the systematic review and meta-analysis, and the search strategy was based on the population, intervention, control and outcome (PICO) model. The Health Sciences Research databases was accessed via EBSCO-host, and EMBASE were searched for relevant articles. Searches were conducted from inception of the databases until 17 September 2021. Results: The results identified three distinct areas: glycaemic control, lipid parameters and body mass index. It was found that COVID-19 lockdown led to a significant (p < 0.01) increase in the levels of glycated haemoglobin (%) compared with pre-COVID group (gp) with a mean difference of 0.34 (95% CI: 0.30, 0.38). Eleven studies contributed to the data for glycated haemoglobin analysis with a total of 16,895 participants (post-COVID-19 lockdown gp, n = 8417; pre-COVID gp, n = 8478). The meta-analysis of fasting plasma glucose (mg/dL) also showed a significant (p < 0.05) increase in levels of post-COVID-19 lockdown gp compared with pre-COVID gp, with a mean difference of 7.19 (95% CI: 5.28, 9.10). Six studies contributed to fasting plasma glucose analysis involving a total of 2327 participants (post-COVID-19 lockdown, n = 1159; pre-COVID gp, n = 1168). The body mass index (BMI) (kg/m2) analysis also demonstrated that post-COVID-19 lockdown gp had a significantly (p < 0.05) higher BMI than the pre-COVID gp with a mean difference of 1.13 (95% CI: 0.99; 1.28), involving six studies and a total of 2363 participants (post-COVID-19 lockdown gp, n = 1186; pre-COVID gp, n = 1177). There were significantly (p < 0.05) lower levels of total cholesterol (mmol/L), triglyceride (mmol/L) and LDL cholesterol (mmol/L), and higher levels of HDL cholesterol (mg/dL) in the post-COVID-19 lockdown gp compared with pre-COVID gp, although these results were not consistent following sensitivity analysis. Conclusion: The findings of the systematic review and meta-analysis have demonstrated that COVID-19 lockdown resulted in a significant increase (p < 0.05) in the levels of glycated haemoglobin, fasting glucose and body mass index in patients with type 2 diabetes. In contrast, the effect of the lockdown on lipid parameters, including total cholesterol, triglycerides, LDL and HDL cholesterol was not consistent.
- Open Access
The Effects of Almonds on Gut Microbiota, Glycometabolism, and Inflammatory Markers in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
The use of nutritional interventions for managing diabetes is one of the effective strategies aimed at reducing the global prevalence of the condition, which is on the rise. Almonds are the most consumed tree nut and they are known to be rich sources of protein, monounsaturated fatty acids, essential minerals, and dietary fibre. Therefore, the aim of this review was to evaluate the effects of almonds on gut microbiota, glycometabolism, and inflammatory parameters in patients with type 2 diabetes. Methods: This systematic review and meta-analysis was carried out according to the preferred reporting items for systematic review and meta-analysis (PRISMA). EBSCOhost, which encompasses the Health Sciences Research Databases; Google Scholar; EMBASE; and the reference lists of articles were searched based on population, intervention, control, outcome, and study (PICOS) framework. Searches were carried out from database inception until 1 August 2021 based on medical subject headings (MesH) and synonyms. The meta-analysis was carried out with the Review Manager (RevMan) 5.3 software. Results: Nine randomised studies were included in the systematic review and eight were used for the meta-analysis. The results would suggest that almond-based diets have significant effects in promoting the growth of short-chain fatty acid (SCFA)-producing gut microbiota. Furthermore, the meta-analysis showed that almond-based diets were effective in significantly lowering (p < 0.05) glycated haemoglobin (HbA1c) levels and body mass index (BMI) in patients with type 2 diabetes. However, it was also found that the effects of almonds were not significant (p > 0.05) in relation to fasting blood glucose, 2 h postprandial blood glucose, inflammatory markers (C-reactive protein and Tumour necrosis factor α, TNF-α), glucagon-like peptide-1 (GLP-1), homeostatic model assessment of insulin resistance (HOMA–IR), and fasting insulin. The biological mechanisms responsible for the outcomes observed in this review in relation to reduction in HbA1c and BMI may be based on the nutrient composition of almonds and the biological effects, including the high fibre content and the low glycaemic index profile. Conclusion: The findings of this systematic review and meta-analysis have shown that almond-based diets may be effective in promoting short-chain fatty acid-producing bacteria and lowering glycated haemoglobin and body mass index in patients with type 2 diabetes compared with control. However, the effects of almonds were not significant (p > 0.05) with respect to fasting blood glucose, 2 h postprandial blood glucose, inflammatory markers (C-reactive protein and TNF-α), GLP-1, HOMA–IR, and fasting insulin.
Open AccessThe Effects of Almonds on Gut Microbiota, Glycometabolism, and Inflammatory Markers in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
The use of nutritional interventions for managing diabetes is one of the effective strategies aimed at reducing the global prevalence of the condition, which is on the rise. Almonds are the most consumed tree nut and they are known to be rich sources of protein, monounsaturated fatty acids, essential minerals, and dietary fibre. Therefore, the aim of this review was to evaluate the effects of almonds on gut microbiota, glycometabolism, and inflammatory parameters in patients with type 2 diabetes. Methods: This systematic review and meta-analysis was carried out according to the preferred reporting items for systematic review and meta-analysis (PRISMA). EBSCOhost, which encompasses the Health Sciences Research Databases; Google Scholar; EMBASE; and the reference lists of articles were searched based on population, intervention, control, outcome, and study (PICOS) framework. Searches were carried out from database inception until 1 August 2021 based on medical subject headings (MesH) and synonyms. The meta-analysis was carried out with the Review Manager (RevMan) 5.3 software. Results: Nine randomised studies were included in the systematic review and eight were used for the meta-analysis. The results would suggest that almond-based diets have significant effects in promoting the growth of short-chain fatty acid (SCFA)-producing gut microbiota. Furthermore, the meta-analysis showed that almond-based diets were effective in significantly lowering (p < 0.05) glycated haemoglobin (HbA1c) levels and body mass index (BMI) in patients with type 2 diabetes. However, it was also found that the effects of almonds were not significant (p > 0.05) in relation to fasting blood glucose, 2 h postprandial blood glucose, inflammatory markers (C-reactive protein and Tumour necrosis factor α, TNF-α), glucagon-like peptide-1 (GLP-1), homeostatic model assessment of insulin resistance (HOMA–IR), and fasting insulin. The biological mechanisms responsible for the outcomes observed in this review in relation to reduction in HbA1c and BMI may be based on the nutrient composition of almonds and the biological effects, including the high fibre content and the low glycaemic index profile. Conclusion: The findings of this systematic review and meta-analysis have shown that almond-based diets may be effective in promoting short-chain fatty acid-producing bacteria and lowering glycated haemoglobin and body mass index in patients with type 2 diabetes compared with control. However, the effects of almonds were not significant (p > 0.05) with respect to fasting blood glucose, 2 h postprandial blood glucose, inflammatory markers (C-reactive protein and TNF-α), GLP-1, HOMA–IR, and fasting insulin.
- Open Access
The Effect of Dietary Fibre on Gut Microbiota, Lipid Profile, and Inflammatory Markers in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Background: A disequilibrium of the gut microbial community has been closely associated with systemic inflammation and metabolic syndromes including type 2 diabetes. While low fibre and high fat diets may lead to dysbiosis of the gut microbiome as a result of the loss of useful microbes, it has been reported that a high fibre diet may prevent the fermentation of protein and may promote eubiosis of gut microbiota. Aim: This review aims to evaluate the effect of dietary fibre (DF) on gut microbiota, lipid profile, and inflammatory markers in patients with type 2 diabetes. Methods: The PRISMA framework was relied on to conduct this systematic review and meta-analysis. Searches were carried out using electronic databases and reference list of articles. Results: Eleven studies were included in the systematic review, while ten studies were included in the meta-analysis. The findings revealed five distinct areas including the effects of DF on (a) gut microbiota (122 participants); (b) lipopolysaccharides (LPS, 79 participants) and lipopolysaccharides binding protein (LBP, 81 participants); (c) lipid profile; (d) inflammatory markers; and (e) body mass index (BMI, 319 participants). The relative abundance of Bifidobacterium increased by 0.73 (95% CI: 0.57, 0.89) in the DF group in contrast to the control (p < 0.05). With respect to LPS, the level was lower in the DF group than the control and the difference was significant (p < 0.05). The standardised mean difference for LPS was −0.45 (95% CI: −0.90, −0.01) although the difference between the two groups in relation to LBP was not significant (p = 0.08) and the mean difference was 0.92 (95% CI: −0.12, 1.95). While there was a decrease of −1.05 (95% CI: −2.07, −0.02) with respect to total cholesterol (356 participants) in the DF group as compared with the control (p < 0.05), both groups were not significantly different (p > 0.05) in the other lipid parameters. The difference between the groups was significant (p < 0.05) in relation to C-reactive protein, and the mean difference was 0.43 (95% CI: 0.02, 0.84). This could be due to the short duration of the included studies and differences in participants’ diets including the amount of dietary fibre supplements. However, the groups were not significantly different (p > 0.05) with respect to the other inflammatory markers. The meta-analysis of the BMI showed that the DF group decreased by −0.57 (95% CI: −1.02, −0.12) as compared with the control and this was significant (p < 0.01). Conclusion: DF significantly (p < 0.05) increased the relative abundance of Bifidobacterium and significantly decreased (p < 0.05) LPS, total cholesterol, and BMI as compared with the control. However, DF did not seem to have an effect that was significant on LBP, triglyceride, HDL cholesterol, LDL cholesterol, IL-6, TNF-α, adiponectin, and leptin. These findings have implications for public health in relation to the use of dietary fibre in nutritional interventions and as strategies for managing type 2 diabetes.
Open AccessThe Effect of Dietary Fibre on Gut Microbiota, Lipid Profile, and Inflammatory Markers in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Background: A disequilibrium of the gut microbial community has been closely associated with systemic inflammation and metabolic syndromes including type 2 diabetes. While low fibre and high fat diets may lead to dysbiosis of the gut microbiome as a result of the loss of useful microbes, it has been reported that a high fibre diet may prevent the fermentation of protein and may promote eubiosis of gut microbiota. Aim: This review aims to evaluate the effect of dietary fibre (DF) on gut microbiota, lipid profile, and inflammatory markers in patients with type 2 diabetes. Methods: The PRISMA framework was relied on to conduct this systematic review and meta-analysis. Searches were carried out using electronic databases and reference list of articles. Results: Eleven studies were included in the systematic review, while ten studies were included in the meta-analysis. The findings revealed five distinct areas including the effects of DF on (a) gut microbiota (122 participants); (b) lipopolysaccharides (LPS, 79 participants) and lipopolysaccharides binding protein (LBP, 81 participants); (c) lipid profile; (d) inflammatory markers; and (e) body mass index (BMI, 319 participants). The relative abundance of Bifidobacterium increased by 0.73 (95% CI: 0.57, 0.89) in the DF group in contrast to the control (p < 0.05). With respect to LPS, the level was lower in the DF group than the control and the difference was significant (p < 0.05). The standardised mean difference for LPS was −0.45 (95% CI: −0.90, −0.01) although the difference between the two groups in relation to LBP was not significant (p = 0.08) and the mean difference was 0.92 (95% CI: −0.12, 1.95). While there was a decrease of −1.05 (95% CI: −2.07, −0.02) with respect to total cholesterol (356 participants) in the DF group as compared with the control (p < 0.05), both groups were not significantly different (p > 0.05) in the other lipid parameters. The difference between the groups was significant (p < 0.05) in relation to C-reactive protein, and the mean difference was 0.43 (95% CI: 0.02, 0.84). This could be due to the short duration of the included studies and differences in participants’ diets including the amount of dietary fibre supplements. However, the groups were not significantly different (p > 0.05) with respect to the other inflammatory markers. The meta-analysis of the BMI showed that the DF group decreased by −0.57 (95% CI: −1.02, −0.12) as compared with the control and this was significant (p < 0.01). Conclusion: DF significantly (p < 0.05) increased the relative abundance of Bifidobacterium and significantly decreased (p < 0.05) LPS, total cholesterol, and BMI as compared with the control. However, DF did not seem to have an effect that was significant on LBP, triglyceride, HDL cholesterol, LDL cholesterol, IL-6, TNF-α, adiponectin, and leptin. These findings have implications for public health in relation to the use of dietary fibre in nutritional interventions and as strategies for managing type 2 diabetes.
- Open Access
- 21 December 2020
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 17  (24) , 9563
The Microbial Quality and Safety of Blenderised Enteral Nutrition Formula: A Systematic Review
The use of blenderised enteral nutrition formula (ENF) is on the increase globally. However, concerns remain regarding the microbial quality and safety of blenderised ENF compared with standard recommendations and commercial ENF. Aim: This was a systematic review which sought to compare the microbial quality of blenderised ENF and commercial ENF and to evaluate the effect of storage time on blenderised ENF. Method: Four databases (Pubmed, EMBASE, PSYCInfo and Google scholar) were searched for relevant articles based on the Population, Intervention, Comparator, Outcomes framework. Results: Eleven studies which met the criteria were included in the systematic review. Two major areas were identified; Microbial Quality of Blenderised ENF versus Commercial ENF; and The Effect of Storage Time on Microbial Quality of Blenderised ENF. Overall, 72.7% of the studies showed microbial contamination in blenderised ENF compared with 57.1% of commercial ENF, and the storage time was another important factor in the rates of contamination. The extent of handling or manipulation of the enteral formula was critical in determining the level of contamination. Conclusion: Preparation techniques for blenderised ENF need to be established and caregivers taught how to prepare and administer it appropriately in order to reduce contamination. Further, well-designed studies are required, which compare the microbial quality of blenderised ENF using adequate handling techniques and commercial ENF.
- 21 December 2020
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 17  (24) , 9563
Open AccessThe Microbial Quality and Safety of Blenderised Enteral Nutrition Formula: A Systematic Review
The use of blenderised enteral nutrition formula (ENF) is on the increase globally. However, concerns remain regarding the microbial quality and safety of blenderised ENF compared with standard recommendations and commercial ENF. Aim: This was a systematic review which sought to compare the microbial quality of blenderised ENF and commercial ENF and to evaluate the effect of storage time on blenderised ENF. Method: Four databases (Pubmed, EMBASE, PSYCInfo and Google scholar) were searched for relevant articles based on the Population, Intervention, Comparator, Outcomes framework. Results: Eleven studies which met the criteria were included in the systematic review. Two major areas were identified; Microbial Quality of Blenderised ENF versus Commercial ENF; and The Effect of Storage Time on Microbial Quality of Blenderised ENF. Overall, 72.7% of the studies showed microbial contamination in blenderised ENF compared with 57.1% of commercial ENF, and the storage time was another important factor in the rates of contamination. The extent of handling or manipulation of the enteral formula was critical in determining the level of contamination. Conclusion: Preparation techniques for blenderised ENF need to be established and caregivers taught how to prepare and administer it appropriately in order to reduce contamination. Further, well-designed studies are required, which compare the microbial quality of blenderised ENF using adequate handling techniques and commercial ENF.
- Open Access
- 30 October 2020
- Published by MDPI AG in Proceedings
- Vol. 61  (1) , 28
Dietary Fibre, Gut Microbiota Dysbiosis and Type 2 Diabetes
Background: Diabetes prevalence is on the increase globally and its impact on those with the condition in terms of acute and chronic complications can be profound. People with type 2 diabetes constitute the majority of those with the condition and the risk factors include obesity, lifestyle and gut microbiota dysbiosis. Poor dietary intake has been reported to influence the community of the gut microbiome. Therefore, a higher intake of dietary fibre may alter the environment in the gut and promote microbial growth and proliferation. Aim: This is a systematic review and meta-analysis which examined the effect of dietary fibre on gut microbiota in patients with type 2 diabetes. Method: This review was conducted in line with the PRISMA framework. Databases were searched for relevant articles which were screened based on inclusion and exclusion criteria. Results: Nine articles which met the inclusion criteria were selected for the systematic review and meta-analysis. High dietary fibre intake significantly improved (p < 0.05) the abundance of Bifidobacterium, total short-chain fatty acids (SCFAs) and HbA1c. Discussion: The promotion of SCFA producers in terms of greater diversity and abundance by dietary fibre may have resulted in improvement in glycated haemoglobin, partly due to increased GLP–1 production. Conclusion: High consumption of dietary fibre has a significant (p < 0.05) effect on Bifidobacterium, total SCFAs and HbA1c, but not (p > 0.05) on propionic, butyric and acetic acid, fasting blood glucose and the homeostatic model assessment of insulin resistance HOMAR–IR.
- 30 October 2020
- Published by MDPI AG in Proceedings
- Vol. 61  (1) , 28
Open AccessDietary Fibre, Gut Microbiota Dysbiosis and Type 2 Diabetes
Background: Diabetes prevalence is on the increase globally and its impact on those with the condition in terms of acute and chronic complications can be profound. People with type 2 diabetes constitute the majority of those with the condition and the risk factors include obesity, lifestyle and gut microbiota dysbiosis. Poor dietary intake has been reported to influence the community of the gut microbiome. Therefore, a higher intake of dietary fibre may alter the environment in the gut and promote microbial growth and proliferation. Aim: This is a systematic review and meta-analysis which examined the effect of dietary fibre on gut microbiota in patients with type 2 diabetes. Method: This review was conducted in line with the PRISMA framework. Databases were searched for relevant articles which were screened based on inclusion and exclusion criteria. Results: Nine articles which met the inclusion criteria were selected for the systematic review and meta-analysis. High dietary fibre intake significantly improved (p < 0.05) the abundance of Bifidobacterium, total short-chain fatty acids (SCFAs) and HbA1c. Discussion: The promotion of SCFA producers in terms of greater diversity and abundance by dietary fibre may have resulted in improvement in glycated haemoglobin, partly due to increased GLP–1 production. Conclusion: High consumption of dietary fibre has a significant (p < 0.05) effect on Bifidobacterium, total SCFAs and HbA1c, but not (p > 0.05) on propionic, butyric and acetic acid, fasting blood glucose and the homeostatic model assessment of insulin resistance HOMAR–IR.